rs150452237

Variant summary

Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_005670.4(EPM2A):ā€‹c.376A>Gā€‹(p.Ile126Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000509 in 1,613,832 control chromosomes in the GnomAD database, including 8 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: š‘“ 0.00045 ( 0 hom., cov: 32)
Exomes š‘“: 0.00051 ( 8 hom. )

Consequence

EPM2A
NM_005670.4 missense

Scores

18

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:5

Conservation

PhyloP100: 0.883
Variant links:
Genes affected
EPM2A (HGNC:3413): (EPM2A glucan phosphatase, laforin) This gene encodes a dual-specificity phosphatase and may be involved in the regulation of glycogen metabolism. The protein acts on complex carbohydrates to prevent glycogen hyperphosphorylation, thus avoiding the formation of insoluble aggregates. Loss-of-function mutations in this gene have been associated with Lafora disease, a rare, adult-onset recessive neurodegenerative disease, which results in myoclonus epilepsy and usually results in death several years after the onset of symptoms. The disease is characterized by the accumulation of insoluble particles called Lafora bodies, which are derived from glycogen. [provided by RefSeq, Jan 2018]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.007952094).
BP6
Variant 6-145686222-T-C is Benign according to our data. Variant chr6-145686222-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 167038.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=2, Benign=3}.
BS1
Variant frequency is greater than expected in population mid. gnomad4_exome allele frequency = 0.000515 (752/1461524) while in subpopulation MID AF= 0.00277 (16/5768). AF 95% confidence interval is 0.00174. There are 8 homozygotes in gnomad4_exome. There are 418 alleles in male gnomad4_exome subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAdExome4 at 8 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
EPM2ANM_005670.4 linkuse as main transcriptc.376A>G p.Ile126Val missense_variant 2/4 ENST00000367519.9

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
EPM2AENST00000367519.9 linkuse as main transcriptc.376A>G p.Ile126Val missense_variant 2/41 NM_005670.4 P1O95278-1

Frequencies

GnomAD3 genomes
AF:
0.000453
AC:
69
AN:
152190
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000965
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.0112
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00104
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00637
Gnomad NFE
AF:
0.000235
Gnomad OTH
AF:
0.000478
GnomAD3 exomes
AF:
0.000867
AC:
218
AN:
251418
Hom.:
2
AF XY:
0.000949
AC XY:
129
AN XY:
135888
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000174
Gnomad ASJ exome
AF:
0.0103
Gnomad EAS exome
AF:
0.0000544
Gnomad SAS exome
AF:
0.00189
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000352
Gnomad OTH exome
AF:
0.00147
GnomAD4 exome
AF:
0.000515
AC:
752
AN:
1461524
Hom.:
8
Cov.:
32
AF XY:
0.000575
AC XY:
418
AN XY:
727096
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.000201
Gnomad4 ASJ exome
AF:
0.0114
Gnomad4 EAS exome
AF:
0.0000504
Gnomad4 SAS exome
AF:
0.00176
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000187
Gnomad4 OTH exome
AF:
0.00113
GnomAD4 genome
AF:
0.000453
AC:
69
AN:
152308
Hom.:
0
Cov.:
32
AF XY:
0.000295
AC XY:
22
AN XY:
74472
show subpopulations
Gnomad4 AFR
AF:
0.0000962
Gnomad4 AMR
AF:
0.000131
Gnomad4 ASJ
AF:
0.0112
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00104
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000235
Gnomad4 OTH
AF:
0.000473
Alfa
AF:
0.000833
Hom.:
2
Bravo
AF:
0.000499
TwinsUK
AF:
0.00
AC:
0
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.000791
AC:
96
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.000491
EpiControl
AF:
0.000533

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:5
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Benign:2
Benign, criteria provided, single submitterclinical testingGeneDxApr 09, 2019- -
Likely benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenJun 01, 2023EPM2A: BP4 -
Cataract;C1837397:Severe global developmental delay;C4551563:Microcephaly Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingCentre for Mendelian Genomics, University Medical Centre LjubljanaJan 01, 2017- -
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsSep 21, 2017The p.I126V variant (also known as c.376A>G), located in coding exon 2 of the EPM2A gene, results from an A to G substitution at nucleotide position 376. The isoleucine at codon 126 is replaced by valine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
not specified Benign:1
Benign, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Mar 14, 2014- -
EPM2A-related disorder Benign:1
Benign, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesMar 23, 2020This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Progressive myoclonic epilepsy Benign:1
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 28, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
-0.35
T
BayesDel_noAF
Benign
-0.28
CADD
Benign
11
DANN
Benign
0.70
DEOGEN2
Benign
0.089
T;.;.;.
Eigen
Benign
-0.90
Eigen_PC
Benign
-0.75
FATHMM_MKL
Benign
0.52
D
LIST_S2
Benign
0.66
T;T;.;T
M_CAP
Benign
0.020
T
MetaRNN
Benign
0.0080
T;T;T;T
MetaSVM
Benign
-0.64
T
MutationAssessor
Benign
0.0
N;N;N;N
MutationTaster
Benign
0.98
N
PrimateAI
Benign
0.28
T
PROVEAN
Benign
0.010
N;.;.;.
REVEL
Benign
0.25
Sift
Benign
0.72
T;.;.;.
Sift4G
Benign
0.87
T;T;.;.
Polyphen
0.0
B;B;B;.
Vest4
0.28
MVP
0.76
MPC
0.20
ClinPred
0.0014
T
GERP RS
1.8
gMVP
0.39

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs150452237; hg19: chr6-146007358; API